• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Side Effects in Depression
RESEARCH UPDATE

Side Effects in Depression

October 30, 2022
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Fernando Espí Forcén, MD. Dr. Forcén has no financial relationships with companies related to this material.

REVIEW OF: Braund  TA et al, Transl Psychiatry 2021;11(1):417

STUDY TYPE: Secondary analysis of a randomized controlled trial

Side effects are burdensome to patients, but do they also get in the way of recovery? This study sought to clarify how side effects change over time and whether they impede recovery in major depressive disorder.

This was a secondary analysis of the International Study to Predict Optimized Treatment in Depression (iSPOT-D) trial, a randomized controlled trial that began in 2008 and is still ongoing. The trial randomized adults in psychiatric and primary care clinics with major depression to open-label treatment with escitalopram, sertraline, or venlafaxine XR (there was no placebo arm). This analysis gathered data from 1,008 participants (mean age 38) at day 4 and weeks 2, 4, 6, and 8. Side effects were assessed with a seven-point patient-rated scale, the Frequency, Intensity, and Burden of Side Effects Rating scale. Depression was measured with the Hamilton Depression Rating Scale (HDRS) and the Quick Inventory of Depressive Symptomatology (QIDS), and anxiety was assessed with the anxiety/somatization factor in the HDRS. A linear mixed-effects model tested whether side effects or anxiety had any effect on mood outcomes.

The frequency and intensity of side effects peaked at week 2 and then tended to fade over the next six weeks. However, the perceived burden of these side effects did not diminish over time. Frequency and intensity were not associated with mood outcomes, while the perceived burden of side effects was associated with poorer outcomes on the patient-rated QIDS but not the clinician-rated HDRS. This association between burden and mood outcomes was detectable at day 4 and remained significant until the end of the study. Anxiety did not influence the outcomes, and neither did the type of antidepressant.

The main weakness of this study was that side effects were assessed globally rather than specifically. Also, the study was a secondary analysis of a trial that was not designed to test the study’s hypothesis.

CARLAT TAKE
Side effects of SSRIs and SNRIs tend to peak after a couple weeks and then fade over time. However, the burden of these side effects may remain even as their intensity decreases, and lingering side effects can get in the way of recovery from depression.

General Psychiatry
KEYWORDS anxiety disorders depression mood disorders research update side effects
    www.thecarlatreport.com
    Issue Date: October 30, 2022
    SUBSCRIBE NOW
    Table Of Contents
    Does Abortion Lead to Psychiatric Issues?
    The Enduring Value of Talking Therapy
    Trichotillomania: Diagnosis and Treatment
    Side Effects in Depression
    Who Responds to SSRIs in PTSD?
    CME Post-Test, Psychotherapy, TCPR, December 2022
    DOWNLOAD NOW
    Featured Book
    • MFB6eCover.jpg

      Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

      Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto22709844.jpg
      General Psychiatry

      Psychopharm Commandment #10: Don’t Fear these Meds

      Surprising health benefits of our riskiest meds: Lithium, quetiapine, and clozapine.

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.